Resmed Inc (NYQ:RMD) cover image
162 Reads (3 mins read)

Can Resmed Inc's high return on equity take it to the next level?

5th Jun '20 by Ben Hobson

Quick question – what do you think is the main role of a company’s senior management team? Long-term business strategy? Earnings growth? Making sure the wheels don’t fall off?

Top analysts and investors such as Warren Buffett and Michael Mauboussin say the answer is capital allocation - the deployment of company time, money, ideas, and people in ways that create additional value. It is perhaps the most fundamental driver of future share price performance. If you find a company that consistently allocates its capital profitably, chances are you are onto a long-term winner.

Unfortunately, CEOs are not generally promoted based on their ability to allocate capital, even though this is what they then go on to spend time doing. As Mauboussin writes in one of his research papers:

Capital allocation is one of management’s prime responsibilities. Yet few senior executives are versed or trained in methods to allocate capital most effectively. Further, incentive programs frequently encourage behaviors that are not in the best interests of long-term shareholders.

So if you’re only looking at sales and earnings growth, there is a vital question not being considered: how is this growth being funded?


Finding upwardly mobile, high-quality companies

That’s where ratios like return on equity (ROE) come in. ROE measures how efficiently a company uses Shareholders’ Equity to generate profits. It is calculated by dividing net income by book value of equity.

It’s no coincidence that Buffett is a fan of the measure - companies with high ROEs tend to exhibit the high-quality, moat-like business traits that he is so fond of gaining exposure to.

What we want to find are high ROE stocks whose fantastic business models are being rewarded by the market. One way to do this might be to screen for shares with both positive one-year relative strength and upgraded current year broker forecasts. The former ensures these shares have been outperforming the market, and the latter suggests the outperformance can continue.

One stock that currently qualifies for this screen is Resmed Inc (NYQ:RMD). The group has:

  • A trailing twelve month return on equity of 24.1%
  • An average current year EPS forecast upgrade of 4.21% from brokers, and
  • A one-year relative strength of 30.1%

Stocks exhibiting these traits are typically a solid mix of quality and momentum. We can see this using another set of metrics: Resmed Inc has a Quality Rank of 99 and a Momentum Rank of 97.

Studies indicate that combining factors such as Value, Quality and Momentum is a more effective way of outperforming the market over longer time frames. That's why we have constructed our StockReports to give an instant impression of how well exposed Resmed Inc (NYQ:RMD) is to these three factors. We go into greater detail on factor investing in this video

Stockopedia helps you to identify return-enhancing factors such as Quality, Value and Momentum by analysing thousands of data points every day. To find out more about you find investment opportunities and analyse your portfolios then take one of our two-week free trials and have a look around.

Share this article
As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.
Share Price
Change Today
Resmed Inc ( )

Stockopedia is here to help individual investors beat the markets by being the very best in stock analysis, research & community. Take a 30 day free trial of our extensive multi-award winning service and find out why more than ten thousand global investors can't live without it.

© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.